Trade Dechra Pharmaceuticals PLC - DPH CFD

Add to favourite

38.18

0.05%

View detailed chart

0.20

Low: 38.16

High: 38.2

Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.20

Long position overnight fee

-0.025262%

Short position overnight fee

0.003344%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

GBP

Margin

20%

Stock exchange

United Kingdom of Great Britain and Northern Ireland

Commission on trade

*Information provided by Capital.com

Dechra Pharmaceuticals PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	38.16
Open*	38.16
1-Year Change*	41.12%
Day's Range*	38.16 - 38.2
52 wk Range	24.73-40.00
Average Volume (10 days)	892.50K
Average Volume (3 months)	17.33M
Market Cap	4.35B
P/E Ratio	-100.00K
Shares Outstanding	113.89M
Revenue	761.50M
EPS	-0.24
Dividend (Yield %)	1.1876
Beta	0.95
Next Earnings Date	Feb 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 30, 2023	38.16	0.02	0.05%	38.14	38.18	37.92
Nov 29, 2023	38.16	0.04	0.10%	38.12	38.20	38.12
Nov 28, 2023	38.16	0.08	0.21%	38.08	38.16	38.08
Nov 27, 2023	38.16	0.26	0.69%	37.90	38.16	37.90
Nov 24, 2023	38.14	0.04	0.10%	38.10	38.14	38.10
Nov 23, 2023	38.12	0.02	0.05%	38.10	38.14	38.10
Nov 22, 2023	38.12	0.34	0.90%	37.78	38.12	37.78
Nov 21, 2023	38.10	0.02	0.05%	38.08	38.10	38.04
Nov 20, 2023	38.10	0.00	0.00%	38.10	38.16	38.06
Nov 17, 2023	38.14	0.44	1.17%	37.70	38.24	37.50
Nov 16, 2023	37.70	-0.02	-0.05%	37.72	37.80	37.66
Nov 15, 2023	37.54	-0.20	-0.53%	37.74	37.80	37.52
Nov 14, 2023	37.76	0.06	0.16%	37.70	37.82	37.56
Nov 13, 2023	37.76	0.42	1.12%	37.34	37.78	37.34
Nov 10, 2023	37.70	-0.04	-0.11%	37.74	37.78	37.64
Nov 9, 2023	37.76	0.02	0.05%	37.74	37.88	37.64
Nov 8, 2023	37.68	0.14	0.37%	37.54	37.78	37.54
Nov 7, 2023	37.72	0.00	0.00%	37.72	37.82	37.72
Nov 6, 2023	37.82	0.06	0.16%	37.76	37.86	37.72
Nov 3, 2023	37.72	-0.04	-0.11%	37.76	37.82	37.58

Dechra Pharmaceuticals PLC Events

Time (UTC)	Country	Event
Wednesday, December 13, 2023
Time (UTC) 10:59	Country GB	Event Dechra Pharmaceuticals PLC Annual Shareholders Meeting Dechra Pharmaceuticals PLC Annual Shareholders Meeting Forecast - Previous -
Tuesday, February 27, 2024
Time (UTC) 10:59	Country GB	Event Half Year 2024 Dechra Pharmaceuticals PLC Earnings Release Half Year 2024 Dechra Pharmaceuticals PLC Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2023	2022	2021	2020	2019
Total revenue	761.5	681.8	608	515.1	481.8
Revenue	761.5	681.8	608	515.1	481.8
Cost of Revenue, Total	331.9	296.5	262.1	223.5	203.6
Gross Profit	429.6	385.3	345.9	291.6	278.2
Total Operating Expense	776.6	599.8	521.2	465.4	443.8
Selling/General/Admin. Expenses, Total	207	178.6	151.3	134.9	125.7
Research & Development	57.5	32.4	32.4	28.4	25.1
Depreciation / Amortization	140.2	72.8	75.2	69.6	76.8
Unusual Expense (Income)	40	19.5	0.2	9	12.6
Operating Income	-15.1	82	86.8	49.7	38
Interest Income (Expense), Net Non-Operating	-21	-4.4	-12.8	-8.8	-10.2
Other, Net					0
Net Income Before Taxes	-36.1	77.6	74	40.9	27.8
Net Income After Taxes	-27.9	58.2	55.5	33.9	20.9
Minority Interest					0
Net Income Before Extra. Items	-27.9	58.2	55.5	33.9	20.9
Net Income	-27.9	58.2	55.5	33.9	30.9
Income Available to Common Excl. Extra. Items	-27.9	58.2	55.5	33.9	20.9
Income Available to Common Incl. Extra. Items	-27.9	58.2	55.5	33.9	30.9
Dilution Adjustment		0
Diluted Net Income	-27.9	58.2	55.5	33.9	30.9
Diluted Weighted Average Shares	113.477	108.987	108.751	103.482	102.762
Diluted EPS Excluding Extraordinary Items	-0.24587	0.53401	0.51034	0.32759	0.20338
Dividends per Share - Common Stock Primary Issue		0.4489	0.405	0.3429	0.316
Diluted Normalized EPS	0.57545	0.95974	0.72643	0.58561	0.59847
Total Extraordinary Items					10

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total revenue	384.1	377.4	349.4	332.4	308.2
Revenue	384.1	377.4	349.4	332.4	308.2
Cost of Revenue, Total	174	158.1	153.3	143.2	133
Gross Profit	210.1	219.3	196.1	189.2	175.2
Total Operating Expense	436.8	339.8	324.2	275.6	262.9
Selling/General/Admin. Expenses, Total	104.5	102.5	96.8	81.8	76.5
Research & Development	31	26.5	18.9	13.5	17.3
Depreciation / Amortization	32.5	38.6	37.4	35.4	36.9
Unusual Expense (Income)	94.8	14.1	17.8	1.7	-0.8
Operating Income	-52.7	37.6	25.2	56.8	45.3
Interest Income (Expense), Net Non-Operating	-13.1	-7.9	-1	-3.4	-6.7
Other, Net
Net Income Before Taxes	-65.8	29.7	24.2	53.4	38.6
Net Income After Taxes	-50.5	22.6	17.5	40.7	32.2
Net Income Before Extra. Items	-50.5	22.6	17.5	40.7	32.2
Net Income	-50.5	22.6	17.5	40.7	32.2
Income Available to Common Excl. Extra. Items	-50.5	22.6	17.5	40.7	32.2
Income Available to Common Incl. Extra. Items	-50.5	22.6	17.5	40.7	32.2
Dilution Adjustment			0
Diluted Net Income	-50.5	22.6	17.5	40.7	32.2
Diluted Weighted Average Shares	113.858	113.824	109.083	108.892	108.803
Diluted EPS Excluding Extraordinary Items	-0.44353	0.19855	0.16043	0.37376	0.29595
Dividends per Share - Common Stock Primary Issue		0.125	0.3289	0.12	0.2939
Diluted Normalized EPS	0.75006	0.42873	0.49595	0.46376	0.46598

Annual
Quarterly

	2023	2022	2021	2020	2019
Total Current Assets	467.9	444.4	392.2	448.9	291.5
Cash and Short Term Investments	74.4	120.9	118.4	227.4	80.3
Cash	74.4	120.9	118.4	227.4	80.3
Short Term Investments
Total Receivables, Net	169.6	142.1	119.2	97.3	103.8
Accounts Receivable - Trade, Net	144.2	122.1	88.2	79.4	91.1
Total Inventory	217.3	175.7	149.5	120.8	103.5
Prepaid Expenses	6.6	5.7	5.1	3.4	3.9
Total Assets	1569.4	1293.3	1214.1	1237.6	1041.5
Property/Plant/Equipment, Total - Net	159.3	100.3	87	76.4	58.4
Property/Plant/Equipment, Total - Gross	224.7	161.9	140	127.8	100.8
Accumulated Depreciation, Total	-65.4	-61.6	-53	-51.4	-42.4
Goodwill, Net	334.5	245.4	236.1	253.8	245.7
Intangibles, Net	587.9	485.1	479.7	438.4	434.9
Long Term Investments	14.9	15.8	17.1	17.4	10.1
Other Long Term Assets, Total	4.9	2.3	2	2.7	0.9
Total Current Liabilities	164	158.7	155.8	137.3	118.1
Accounts Payable	43.4	46	35.2	34.6	31.9
Accrued Expenses	98.8	87.7	74.4	60.5	61.7
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	3.9	3.3	3.1	4.6	1.2
Other Current Liabilities, Total	17.9	21.7	43.1	37.6	23.3
Total Liabilities	814.2	626.5	581.2	600.1	532.4
Total Long Term Debt	500.6	325.8	317.6	353.1	309.6
Long Term Debt	487.6	313.7	304.8	341.3	309.6
Capital Lease Obligations	13	12.1	12.8	11.8	0
Deferred Income Tax	76.3	35.8	48.8	62.6	74.5
Minority Interest
Other Liabilities, Total	73.3	106.2	59	47.1	30.2
Total Equity	755.2	666.8	632.9	637.5	509.1
Common Stock	1.1	1.1	1.1	1.1	1
Additional Paid-In Capital	596	413.9	411.6	409.3	277.9
Retained Earnings (Accumulated Deficit)	171	248.4	232.1	210.8	208.6
Treasury Stock - Common	-0.2
Other Equity, Total	-12.7	3.4	-11.9	16.3	21.6
Total Liabilities & Shareholders’ Equity	1569.4	1293.3	1214.1	1237.6	1041.5
Total Common Shares Outstanding	113.888	108.393	108.215	108.011	102.652

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total Current Assets	467.9	459.3	444.4	376	392.2
Cash and Short Term Investments	74.4	87.9	120.9	123.7	118.4
Cash & Equivalents
Total Receivables, Net	176.2	147.6	147.8	99.9	124.3
Accounts Receivable - Trade, Net	161.9	125.9	136.8	85.6	106.7
Total Inventory	217.3	223.8	175.7	149.4	149.5
Total Assets	1569.4	1744.3	1293.3	1177.7	1214.1
Property/Plant/Equipment, Total - Net	159.3	155.3	100.3	92.3	87
Intangibles, Net	922.4	1111.2	730.5	689.4	715.8
Long Term Investments	14.9	15.4	15.8	17.7	17.1
Other Long Term Assets, Total	4.9	3.1	2.3	2.3	2
Total Current Liabilities	164	168.4	158.7	129.2	155.8
Payable/Accrued	144.5	139.3	136.8	99.9	113.5
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	3.9	3.2	3.3	3.1	3.1
Other Current Liabilities, Total	15.6	25.9	18.6	26.2	39.2
Total Liabilities	814.2	902.6	626.5	538.6	581.2
Total Long Term Debt	500.6	508	325.8	313.7	315.5
Long Term Debt	500.6	508	325.8	313.7	315.5
Deferred Income Tax	76.3	124.8	35.8	43.4	48.8
Other Liabilities, Total	73.3	101.4	106.2	52.3	61.1
Total Equity	755.2	841.7	666.8	639.1	632.9
Common Stock	1.1	1.1	1.1	1.1	1.1
Additional Paid-In Capital	596	594.7	413.9	413.3	411.6
Retained Earnings (Accumulated Deficit)	171	235.4	248.4	242.3	232.1
Treasury Stock - Common	-0.2
Other Equity, Total	-12.7	10.5	3.4	-17.6	-11.9
Total Liabilities & Shareholders’ Equity	1569.4	1744.3	1293.3	1177.7	1214.1
Total Common Shares Outstanding	113.888	113.837	108.393	108.365	108.215
Cash	74.4	87.9	120.9	123.7	118.4
Other Current Assets, Total		0		3

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	95.5	84	52.2	39	34.1
Cash From Operating Activities	122.9	89.1	106.4	81.8	64
Cash From Operating Activities	11.1	11	9.9	5.7	4.8
Amortization	78	4.5	4.3	4.1	2.6
Non-Cash Items	6.5	77.7	69.8	79	63.1
Cash Taxes Paid	32.9	43.9	12.9	17.3	11.5
Cash Interest Paid	7.5	8.2	8.2	9.2	5.7
Changes in Working Capital	-68.2	-88.1	-29.8	-46	-40.6
Cash From Investing Activities	-78.3	-136.1	-81.5	-61.9	-241.7
Capital Expenditures	-77.6	-134.8	-49.2	-22.5	-12.6
Other Investing Cash Flow Items, Total	-0.7	-1.3	-32.3	-39.4	-229.1
Cash From Financing Activities	-46.1	-55.1	118.9	-20.1	193.8
Financing Cash Flow Items		0	-1.7	-0.2	-3.9
Total Cash Dividends Paid	-44.8	-37.9	-33.3	-28.4	-21.8
Issuance (Retirement) of Stock, Net	2.3	2.3	131.5	1.2	103.3
Issuance (Retirement) of Debt, Net	-3.6	-19.5	22.4	7.3	116.2
Foreign Exchange Effects	4	-6.9	3.3	0.8	2.4
Net Change in Cash	2.5	-109	147.1	0.6	18.5

	Dec 2022	Jun 2022	Dec 2021	Jun 2021	Dec 2020
Net income/Starting Line	44.6	95.5	57.4	84	40.3
Cash From Operating Activities	51.5	122.9	88.1	89.1	58.1
Cash From Operating Activities	6.2	11.1	5.2	11	5.3
Amortization	39.3	78	37.6	4.5	2.1
Non-Cash Items	3.9	6.5	1.4	77.7	41.2
Cash Taxes Paid	10.4	32.9	11.6	43.9	22.8
Cash Interest Paid	3.3	7.5	3.6	8.2	4.2
Changes in Working Capital	-42.5	-68.2	-13.5	-88.1	-30.8
Cash From Investing Activities	-408.2	-78.3	-49.8	-136.1	-116.2
Capital Expenditures	-13.6	-77.6	-49.5	-134.8	-116.1
Other Investing Cash Flow Items, Total	-394.6	-0.7	-0.3	-1.3	-0.1
Cash From Financing Activities	321.4	-46.1	-32	-55.1	-27.1
Financing Cash Flow Items				0	0
Total Cash Dividends Paid	-37.4	-44.8	-31.8	-37.9	-25.9
Issuance (Retirement) of Stock, Net	180.8	2.3	1.7	2.3	1.3
Issuance (Retirement) of Debt, Net	178	-3.6	-1.9	-19.5	-2.5
Foreign Exchange Effects	2.3	4	-1	-6.9	-3.2
Net Change in Cash	-33	2.5	5.3	-109	-88.4

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
BNP Paribas Asset Management France SAS	Investment Advisor/Hedge Fund	6.7582	7697132	116493	2023-10-26	LOW
Barclays Wealth	Investment Advisor/Hedge Fund	6.5827	7497298	475778	2023-10-26	MED
BlackRock Investment Management (UK) Ltd.	Investment Advisor/Hedge Fund	5.7701	6571802	-303696	2023-10-27	LOW
Société Générale Securities Services S.A.	Research Firm	4.9038	5585132	-429889	2023-10-27	LOW
Ostrum Asset Management	Investment Advisor	4.8093	5477494	13148	2023-10-27	MED
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	4.4274	5042517	23611	2023-10-26	LOW
Norges Bank Investment Management (NBIM)	Sovereign Wealth Fund	3.4318	3908560	-20999	2023-09-14	LOW
NBC Global Finance, Ltd.	Corporation	3.0452	3468246	-1137336	2023-10-26	MED
Bank of Nova Scotia	Bank and Trust	3.0262	3446604	1123723	2023-10-27	MED
Brown Capital Management, LLC	Investment Advisor	2.8876	3288786	-196740	2023-10-20	LOW
UBS Limited	Research Firm	2.4145	2750008	1619452	2023-10-26	HIGH
J.P. Morgan Securities plc	Research Firm	2.3944	2727124	-1236978	2023-09-25	MED
BlackRock Institutional Trust Company, N.A.	Investment Advisor	1.7406	1982380	1989	2023-10-01	LOW
Legal & General Investment Management Ltd.	Investment Advisor/Hedge Fund	1.7196	1958552	-35687	2023-10-27	LOW
Jefferies GmbH	Hedge Fund	1.4955	1703250	328929	2023-07-21	LOW
Rathbone Unit Trust Management Limited	Investment Advisor/Hedge Fund	1.3067	1488270	-305406	2023-10-27	LOW
State Street Global Advisors (US)	Investment Advisor/Hedge Fund	1.1204	1276082	-12	2023-10-26	LOW
Baron Capital Management, Inc.	Investment Advisor/Hedge Fund	1.1172	1272410	-120000	2023-08-18	LOW
Nuveen LLC	Pension Fund	1.0909	1242443	-83027	2023-08-17	LOW
Goldman Sachs International	Research Firm	1.0499	1195823	1195823	2023-06-09	MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Dechra Pharmaceuticals Company profile

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets companion animal, equine, food producing animal products and nutrition. The North American (NA) Pharmaceuticals segment consists of Dechra Veterinary Products US, Dechra Produtas Veterinarios (Mexico) and Dechra Veterinary Products Canada, which sells companion animal, equine and food producing animal products. The segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas.

Financial summary

BRIEF: For the six months ended 31 December 2021, Dechra Pharmaceuticals plc revenues increased 11% to £332.4M. Net income increased 75% to £40.7M. Revenues reflect NA Pharmaceuticals segment increase of 21% to £126.3M, European Pharmaceuticals segment increase of 5% to £206.1M. Net income benefited from NA Pharmaceuticals segment income increase of 20% to £43.6M, European Pharmaceuticals segment income increase of 7% to £69.7M.

Equity composition

12/2007, Rights Issue, 11 new shares for every 50 shares held @ GBp 303 (Factor: 1.018155). 04/2012, Rights Issue, 3 new shares for every 10 shares held @ GBp 300 (Factor: 1.103196).

Industry:

Veterinary Drugs

24 Cheshire Avenue
Cheshire Business Park
NORTHWICH
CHESHIRE CW9 7UA
GB

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023